Related Experiment Video
Updated: Apr 5, 2026
04:53
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
11.5K
Paperless clinical trials: Myth or reality?
1Department of Pharmacology, Dhanalakshmi Srinivasan Medical College and Hospital, Siruvachur, Perambalur, Tamil Nadu, India.
Indian Journal of Pharmacology
|August 20, 2015
Summary
The pharmaceutical industry needs faster drug approvals through technology. Transitioning to paperless clinical trials streamlines processes and enhances efficiency, despite implementation challenges.
Area of Science:
- Clinical research
- Pharmaceutical development
- Regulatory science
Background:
- Drug development faces lengthy timelines and complex processes, impacting efficiency.
- Increasing complexity in clinical trials necessitates technological integration for data management.
- Pharmaceutical organizations aim for streamlined, technology-driven clinical trial operations.
Purpose of the Study:
- To highlight the need for expedited drug time-to-market.
- To explore the benefits of technology-driven clinical trials.
- To discuss the transition towards paperless clinical trial processes.
Main Methods:
- Review of current clinical trial data management practices.
- Analysis of advancements in paperless systems for data capture and management.
- Examination of regulatory authority recommendations for paperless trials.
Main Results:
- Paperless systems improve data capture and management in clinical trials.
- Adoption of paperless processes offers a consistent and streamlined framework.
- Major regulatory authorities support the move towards paperless trials.
Conclusions:
- Transitioning to paperless clinical trials is crucial for competitiveness.
- While beneficial, challenges remain in the implementation of paperless trial processes.
- Further efforts are needed to overcome existing barriers to paperless trial adoption.
Related Concept Videos
01:16Clinical Trials
11.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
11.2K
01:11Clinical Trials: Overview
5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K
01:28Preclinical Development: Overview
6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
01:11Blinding
4.1K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.1K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
210
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
210
01:13Bioequivalence studies: Biowaivers
398
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
398